Innovative Women’s Health Focus Mithra specializes in breakthrough contraception and menopause therapies, using the unique native estrogen estetrol, which positions the company to expand its product portfolio and explore additional therapeutic areas within women’s health features.

Strong Market Expansion Active in over 100 countries, Mithra’s global presence combined with recent investment inflows and licensing agreements provides significant opportunities to partner on distribution, licensing, and commercialization of its innovative products.

Robust Financial Momentum With recent funding rounds totaling over $88 million and milestone payments from licensing deals, Mithra demonstrates strong financial capability to support sales initiatives and fund new product launches or partnerships.

Pipeline and Data Advantage Positive preclinical data on inhibitors for endometriosis, oncology, and inflammatory disorders and existing products like Estelle® and Donesta® indicate a promising pipeline for expanding treatment options and engaging healthcare providers and institutions.

Strategic Collaborations Partnerships with companies like Fuji Pharma and Hydra for licensing and technological scaling create opportunities to leverage existing alliances for joint marketing, distribution channels, and entry into new markets.